Post-operative stereotactic Curie-therapy using the iridium-192 GammaMed contact irradiation apparatus combined with radio-sensitizers in treating multiform glioblastomas.
Experimental investigations on the dimethyl-amino-stilbous carcino-sarcoma of the rat have led to a modified interstitial post-operative Curie-therapy of gliomas in the brain hemispheres following treatment with radio sensitizers. After treatment with the thymine-analogous radio-sensitizers 5-brom-2-desoxyuridine (BUDR) and 5-brom-2-desoxycytidine (BCDR) and desoxyguanosine as well as the anti-metabolites 5-fluor-uracile (FU) and methotrexate (Mtx), there is greater incorporation of the thymine analogues in the DNS of the tumour cells. More than any other combination, BUDR and Mtx effectively sensibilizes the tumour cells. Syncavit and actinomycine-D are also effective. After radio-sensitizing the post-iridium-192 contact irradiation apparatus on 133 patients with gliomas. This treatment lengthened postoperative survival times.
D001932:Brain Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D001972:Bromodeoxycytidine / Q000008:administration & dosage*; D001973:Bromodeoxyuridine / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D005909:Glioblastoma / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D007495:Iridium / Q000008:administration & dosage*; D011184:Postoperative Period; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011868:Radioisotopes / Q000008:administration & dosage*; D011878:Radiotherapy / Q000295:instrumentation; D011879:Radiotherapy Dosage; D013238:Stereotaxic Techniques
D011838:Radiation-Sensitizing Agents; D011868:Radioisotopes; D003841:Deoxycytidine; D001972:Bromodeoxycytidine; D007495:Iridium; D001973:Bromodeoxyuridine